Aller au contenu

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Nom du journal : Int J Gynecol Cancer

Année : 2024

Volume : 34

Page de départ : 550-558

Auteurs: Lorusso, D, Mouret-Reynier, MA, Harter, P, Cropet, C, Caballero, C, Wolfrum-Ristau, P & al,